1 week Ago By Defense World Staff
Corebridge Financial Inc. cut its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 7.
0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 17,213 shares of the company’s stock after selling 1,299 shares during the period. Corebridge Financial Inc.
’s holdings in Spyre Therapeutics were worth $401,000 at the end of the most recent reporting period. A number of other hedge funds and other institutional investors also recently made changes to their positions in SYRE. Wellington Management Group LLP lifted its holdings in Spyre Therapeutics by 89.
4% during the third quarter. Wellington Management Group LLP now owns 1,507,200 shares of the company’s stock worth $44,327,000 after acquiring an additional 711,254 shares in the last quarter. Vanguard Group Inc.
raised its position in shares of Spyre Therapeutics by 13.1% during the fourth quarter. Vanguard Group Inc.
now owns 2,846,473 shares of the company’s stock worth $66,266,000 after purchasing an additional 330,553 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of Spyre Therapeutics during the fourth quarter worth about $6,241,000.
Emerald Advisers LLC lifted its holdings in shares of Spyre Therapeutics by 86.9% during the 4th quarter. Emerald Advisers LLC now owns 546,791 shares of the company’s stock valued at $12,729,000 after purchasing an additional 254,222 shares in the last quarter.
Finally, Candriam S.C.A.
grew its position in shares of Spyre Therapeutics by 135.8% in the 4th quarter. Candriam S.
C.A. now owns 247,591 shares of the company’s stock valued at $5,764,000 after purchasing an additional 142,591 shares during the period.
80.39% of the stock is owned by institutional investors. Spyre Therapeutics Stock Up 13.
3 %Shares of SYRE stock opened at $13.37 on Thursday. The company has a market cap of $805.
64 million, a P/E ratio of -1.79 and a beta of 3.05.
Spyre Therapeutics, Inc. has a twelve month low of $10.91 and a twelve month high of $40.
84. The business has a fifty day simple moving average of $18.91 and a 200 day simple moving average of $24.
51. Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.
81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.08.
As a group, equities research analysts anticipate that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current fiscal year.
Analysts Set New Price TargetsSYRE has been the topic of several research analyst reports. The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a report on Tuesday, February 18th. Wolfe Research began coverage on shares of Spyre Therapeutics in a research report on Tuesday, March 18th.
They issued an “outperform” rating and a $27.00 target price for the company. Wedbush reaffirmed an “outperform” rating and set a $65.
00 price target on shares of Spyre Therapeutics in a research report on Monday, January 13th. Leerink Partners began coverage on shares of Spyre Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $45.
00 target price on the stock. Finally, Leerink Partnrs raised shares of Spyre Therapeutics to a “strong-buy” rating in a research report on Tuesday. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock.
Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $49.57.Read Our Latest Report on SYRESpyre Therapeutics Company Profile (Free Report)Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD).
It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).Featured StoriesFive stocks we like better than Spyre Therapeutics3 Grocery Stocks That Can Help Take a Bite Out of Inflation Quantum Computing: The $6.5 Billion Opportunity You Can’t IgnoreHigh Flyers: 3 Natural Gas Stocks for March 2022Are Tariffs Threatening Disney’s Comeback Story?ESG Stocks, What Investors Should KnowIs Alphabet a Generational Buying Opportunity at These Levels?Want to see what other hedge funds are holding SYRE? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report)..
